Ekso Bionics HoldingsEKSO -0.42%32 EBITDA Margin % is -293.69% as of Mar. 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Ekso Bionics Holdings ranks worse than 85.05% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ekso Bionics Holdings EBITDA Margin % Related Terms
Ekso Bionics Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ekso Bionics Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKSO vs POCI, HBIO, NEPH: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ekso Bionics Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ekso Bionics Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ekso Bionics Holdings (EKSO) has a EBITDA Margin % of -293.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ekso Bionics Holdings and its competitors. According to the industry distribution chart, Ekso Bionics Holdings ranks #694 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Ekso Bionics Holdings' EBITDA Margin % too high?
Ekso Bionics Holdings' current EBITDA Margin % is -293.69%. Based on the distribution chart, Ekso Bionics Holdings ranks #694 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' EBITDA Margin % compare to POCI and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Ekso Bionics Holdings ranks #694 out of 816 companies for EBITDA Margin %. This places Ekso Bionics Holdings in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ekso Bionics Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ekso Bionics Holdings's current EBITDA Margin % is -293.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.31, compared to a current price of $11.65 — trading 170.3% above its estimated fair value. The current EBITDA Margin % is -293.69%. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current EBITDA Margin % is -293.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?
Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued.
The current stock price of $11.65 is trading 170.3% above its estimated GF Value™ of $4.31.
GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.
Key valuation signals for EKSO:
EBITDA Margin %: -293.69%
GF Value™: $4.31 vs. price of $11.65 (170.3% above fair value)
No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score
Get the complete analysis for EKSO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKSO has been successfully added to your 
